Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5140256 | 0.91 | GPR119 (0.53) | GPR119CYP2C9 | |
| SCHEMBL5138897 | 0.89 | GPR119 (0.54) | GPR119CYP2C9 | |
| SCHEMBL5139895 | 0.87 | GPR119 (0.52) | GPR119CYP2C9 | |
| SCHEMBL5140036 | 0.86 | GPR119 (0.53) | GPR119CYP2C9 | |
| SCHEMBL5139844 | 0.86 | GPR119 (0.53) | GPR119CYP2C9 | |
| SCHEMBL5138883 | 0.84 | GPR119 (0.70) | GPR119CYP2C9 | |
| SCHEMBL5140322 | 0.84 | GPR119 (0.61) | GPR119CYP2C9 | |
| SCHEMBL1899232 | 0.84 | GPR119 (0.69) | GPR119CYP2C9 | |
| SCHEMBL5140281 | 0.83 | GPR119 (0.47) | GPR119CYP2C9 | |
| SCHEMBL5138732 | 0.82 | GPR119 (0.50) | GPR119CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470699-B2 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-20050070562-A1 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070562-A1 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, SULT2A1 | GPR119 13/4885CYP2C9 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.